Share on LinkedInShare on LinkedIn

ARTICLE · 21 JANUARY 2021

Federal Court Invalidates Janssen ZYTIGA® Patent

On January 14, 2021, the Federal Court issued a decision (Janssen Inc. et al v. Apotex Inc. et al, 2021 FC 7) in the consolidated infringement action brought under s. 6(1)

CanadaIntellectual Property

On January 14, 2021, the Federal Court issued a decision (Janssen Inc. et al v. Apotex Inc. et al, 2021 FC 7) in the consolidated infringement action brought under s. 6(1) of the Patented Medicine (Notice of Compliance) (PM(NOC)) Regulations by Janssen against Apotex, Dr. Reddy's Laboratory, and Pharmascience. In this decision, the Court invalidated the asserted claims of Janssen's Canadian Patent 2,661,422 (the 422 Patent), which claimed the combined use of the two active ingredients found in Janssen's brand name drug ZYTIGA, abiraterone acetate and prednisone, in the treatment of prostate cancer. Concurrently, the Court dealt with Apotex' counterclaim under s. 6(3) of the PM(NOC) Regulations to invalidate the asserted and non-asserted claims of the 422 Patent. This decision provides important lessons and reminders in drafting and prosecuting patent applications relating to use of therapeutic agents in the treatment of diseases.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from